SUN PHARMA’s Speciality business -
Gross sales for Sun Pharma in FY 23 - 43,278 cr
Out of these - aprox 16 pc of sales ( to the tune of 7000 cr ) come from high margin, high entry barrier speciality products that are growing at > 20 pc CAGR. The same is likely to sustain in future as well
Going forward, this speciality drugs portfolio can grow to become really large with fat margins and high return ratios. Sun Pharma is not only investing heavily in R&D to churn out new Speciality drugs, they also have a big enough war chest for acquisitions and in-licensing
Lets go through some of these products that have been commercialised and the ones that are in pipeline -
Commercial products -
- Illumya - used against moderate-severe plaque psoriasis. Clinical trials are in Phase -3 for usage against Psoriatic Arthritis. Illumya is currently sold in US, Australia, Japan, Canada, Europe. Out licensed for China, North Africa Mkts
- Winlevi - topical treatment for acne vulgaris. Currently being sold in US, Canada
- Levulan - used to treat actinic keratoses of face/scalp and upper extremities
- Absorica - used to treat severe recalcitrant nodular acne. Current mkt - US
- Odomzo - used to treat locally advanced basal cell carcinoma ( a form of Skin Cancer ). Current Mkts - US, Canada, Germany, France, Denmark, Switzerland, Spain, Italy, Australia and Israel
- Cequa - used to treat dry eye syndrome. Current mkts - US, Canada. Out licensed for Chinese mkts
- BromSite - used to prevent ocular pain and post operation inflammation undergoing a Cataract Surgery. Current Mkt - US
- Xelpros - used for reduction of elevated intraocular pressure in patients with open angle glaucoma. Current Mkt - US
- Yonsa - used to treat patients with metastatic castration resistant prostate cancer. Current Mkt - US
- Sezaby - only product approved in US to treat seizures in Neonatal patients
Speciality / NCE pipeline -
CTP -543 - for Alopecia areata - completed phase - 3 trials
Illumya - for Psoriatic Arthritis - undergoing phase 3 trials
Nidlegy - for skin cancer - undergoing phase 3 trials
MM-II - to treat pain in Osteoarthritis - Completed phase 2 trials
SCD - 044 - for Atopic Dermatitis - undergoing phase -2 trials
GL0034 - injectable for type -2 diabetes - completed phase - I trials
Summary - Sun Pharma may well be on its way to becoming a speciality giant cum Innovator. It appears - it should only be a matter of time !!!
Disc - holding, biased, not SEBI registered